1. Introduction {#sec1}
===============

Myeloid neoplasms and acute leukemia encompass many different clinical and pathological entities, some with unique genetic features and reflection on risk-stratification and appropriate therapy strategies. According to the World Health Organization (WHO) 2008 classification \[[@B1], [@B2]\], acute myelogeneous leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myelogenous leukemia (CML) are categorized by the presence of specific balanced chromosomal translocations: AML is associated with t(8;21)(q22;q22), inv(16)(p13q22) or t(16;16)(p13;q22), t(15;17)(q22;q12), and 11q23/*MLL* abnormalities; ALL is mainly associated with t(12;21)(p13;q22), t(9;22)(q34;q11.2), and t(1;19)(q23;p13); and CML is characterized by the Ph+ chromosome or t(9;22)(q34;q11.2). It can be said that the translocations above cover approximately 40--50% of childhood and adult AML and ALL and 90--95% of CML patients \[[@B3]--[@B6]\].

PCR method, especially reverse transcription-PCR (RT-PCR), nowadays has been shown to be a sensitive tool in the clinical evaluation of leukemia. As there are many distinct genetic alterations in various leukemia subtypes, it would be extremely labor intensive to evaluate specific fusions via a panel of individual monoplex assays. This can be avoided by the use of multiplex RT-PCR assays with various downstream detection methods, such as gel-based techniques and bead array \[[@B7]--[@B10]\]. Microarray is another useful detection assay. Two biochip-based diagnostic systems were reported: a gel-based biochip by Nasedkina et al. \[[@B11], [@B12]\] and *MLL*Fusion*Chip* and *AML*Fusion*Chip* from France \[[@B13], [@B14]\]. In these previous works, the gel-based biochip only targeted 7 chromosomal translocations, addressing 13 fusion variants in sum, while other two chips covered certain leukemia group. That was far from translocation types needed for the initial screening stage. In addition, the procedure of PCR was very complicated, with at least two parallel nested multiplex reactions. Therefore, we planned to make RT-PCR-microarray assay much easier, hoping to detect the frequently occurring and well-defined translocations in leukemia.

In our study, we described (a) the improvement of multiplex RT-PCR in combination with microarrays analysis system that facilitated the simultaneous detection of 15 chromosomal aberrations, including more than 50 mRNA splice variants with prognostic value; (b) the sensitivity level of each fusion gene in cell lines or clinical patients unique translocations; (c) the application of this method to test 200 leukemia clinical patients; and (d) the potential diagnostic value of this procedure for detection of unusual fusion genes or fusion junctions.

2. Material and Methods {#sec2}
=======================

2.1. Cell Lines and Patient Samples {#sec2.1}
-----------------------------------

The 15 chromosomal translocations studied and the GenBank database references for the genes involved were given in [Table 1](#tab1){ref-type="table"}. Cell lines and some patient samples with unique translocations as positive controls were also used in the study. The leukemic cell line HL-60 served as a negative control. Cells were maintained in RPMI 1640 (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco). Meanwhile, we also constructed fusion fraction RNAs for translocations (e.g., *PLZF-RARA*, *NPM1-RARA*, *CBFB-MYH11* type D, *SIL-TAL1*, and *BCR-ABL* p230) that had neither cell lines nor positive samples. We constructed expression plasmids using pcDNA3.0 vector (Invitrogen, Carlsbad, CA, USA), then transfected the constructed expression plasmids into 293 T cells using Lipofectamine 2000 (Invitrogen), and finally collected cells in TRIzol (Invitrogen) 48 h after transfection.

200 bone marrow samples of ALL, AML, and CML patients were also used in this work for clinical screening. They were received from the Department of Hematology of Shanghai Children\'s Medical Center (Shanghai, China), Ruijin Hospital (Shanghai, China), and Changhai Hospital (Shanghai, China).

2.2. RNA Preparation {#sec2.2}
--------------------

Leukemia cell extract was prepared by the TRIzol (Invitrogen) homogenization method according to the manufacturer\'s recommendations. Total RNA was resuspended in RNase-free water, and its concentration and quality were determined by NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) and by 2% agarose gel electrophoresis. Then the RNA was stored at −80°C.

2.3. Multiplex RT-PCR Primers {#sec2.3}
-----------------------------

We planned to use only one multiplex RT-PCR reaction to detect more than 50 fusion gene variants of 15 chromosomal rearrangements. To reduce the number of primers used in multiple PCR, we designed chimeric forward primers and chimeric reverse primers containing both gene-specific and universal sequences.

The gene-specific portions of the chimeric forward primers for fusion genes in leukemia were designed or modified with the primer analysis software Primer Premier 5.0 (Premier Biosoft International, Palo Alto, CA, USA), based on sequence data of fusion partner genes deposited in GenBank database or from publications \[[@B7]\] ([Table 2](#tab2){ref-type="table"}). We added bacteriophage promoter T7 and SP6 to the 5′ end of the PCR amplifying forward and reverse primers, respectively, as the universal parts. Thus in the first reverse transcription step, the synthesized cDNAs could be linked to SP6 sequence at their 5′end, so that only one reverse universal primer SP6 was required in the following multiple PCR step. In addition, the universal primer, SP6, was 5′-labeled with biotin so that amplicons could be analyzed with microarrays ([Figure 2](#fig2){ref-type="fig"}). We applied *GUS* gene (beta-glucuronidase, M15182) \[[@B15]\] as internal positive control to avoid false-negative results cased by varying RNA quality and handling errors. Oligonucleotide primers were provided by Generay Biotechnology (Shanghai, China).

2.4. Microarray Probes {#sec2.4}
----------------------

Oligonucleotide probes for translocations in leukemia were designed with the primer analysis software Primer Premier 5.0 (Premier Biosoft International), based on cDNA sequences deposited in GenBank. We designed 29 chimeric junction probes for each splice variant already known for fusion gene transcripts of interest, except the *MLL* rearrangements. In addition, 20 unique probes for each fusion genes partner were selected as positive controls in each gene fusion event, which located upstream or downstream of the described breakpoint. This microarray also included one probe for the *GUS* gene served as an internal positive control for the quality of DNA target prepared for hybridization. The sequences of probes were shown in [Table 3](#tab3){ref-type="table"}. All probes were included in triplicate. The probes were 20--30 nucleotides (nt) long, and their specificity and sensitivity were tested by positive samples to ensure the accuracy of the microarray. The probes and biotinylated control probes were spotted onto CapitalBio optical grade aldehyde slides (CapitalBio Corporation, Beijing, China) ([Figure 1](#fig1){ref-type="fig"}). Oligonucleotide probes were synthesized in Sangon Biotech (Shanghai, China).

2.5. Multiplex RT-PCR {#sec2.5}
---------------------

Multiplex RT-PCR was carried out in two steps. For the reverse transcription step, 2 *μ*g of total RNA was incubated at 70°C for 5 min with a mixture of the chimeric reverse primers (3 pmol of each) and then reverse-transcribed at 42°C for 1 h in a total volume of 25 *μ*L containing 200 U M-MLV reverse transcriptase (Promega, Madison, WI, USA), 25 U RNasin Ribonuclease Inhibitor (Promega), 1 mM of each dNTP, 10 mM dithiothreitol, 50 mM Tris-HCl, pH 8.3, 75 mM KCl, and 3 mM MgCl~2~. Then the cDNA reaction mixture was heated at 70°C 15 min to inactivate reverse transcriptase.

For the PCR step, a two-round PCR amplification was carried out. 1 *μ*L cDNA reaction mixture was added to 20 *μ*L of multiplex mixture containing a mixture of chimeric PCR primers (3 pmol of each), 4 pmol the universal primer SP6, 11 mM Tris-HCl, pH 8.3, 55 mM KCl, 1.5 mM MgCl~2~, 15% DMSO, 0.4 mM each of dNTPs, and 1.25 U of ExTaq HS polymerase (Takara, Dalian, LN, China). PCR cycles included 30 cycles of 95°C for 30 s, 55°C for 40 seconds, 72°C for 1 min, and finally 72°C for 7 minutes. After the first PCR, 1 uL of the first round product was added to 20 uL second-round multiplex mixtures that contained 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl~2~, 0.2 mM of each dNTP, 0.4 pmol of forward primers T7 and 4 pmol of reverse primer SP6 (labeled with biotin), and 1 U of ExTaq HS polymerase (Takara). The second PCR consisted of 30 cycles of 95°C for 30 s, 50°C for 30 seconds, 72°C for 1 min, and finally 7 minutes of extension at 72°C. 3 *μ*L of the biotinylated-complexes was electrophoresed on an ethidium bromide stained 2% agarose gel. Negative controls without cDNA template were included for all PCR reaction mixtures.

2.6. Hybridization and Image Analysis {#sec2.6}
-------------------------------------

Microarray firstly was blocked in blocking buffer (2x SSC, 1 mg/mL BSA, 0.2% SDS) for 1 h at room temperature and then washed by pure water. Hybridization was performed in 25 *μ*L hybridization solution (5x SSPE, 0.1 mg/mL Salmon Sperm DNA, 0.5x Denhardt\'s solution, all from Invitrogen) and 20 *μ*L biotin labeled PCR products. Before hybridization, the PCR product was treated with SAP (Takara) and ExoI (Takara) to eliminate primer dimers, then denatured at 94°C, and briefly cooled on ice. Then the hybridization mixture was applied on the hybridization area covered with hybridization chamber (CapitalBio Corporation) and 12--14 h at 46°C. After incubation, the slide was washed in washing solution A (2x SSC, 1% SDS), washing solution B (1x SSC, 0.4% SDS), and washing solution C (0.6x SSC) for 5 min each, followed by incubation in Cy3-Streptavidin (SA) (Invitrogen) 1 h at room temperature. After washing, the fluorescence signal was detected on a GenePix 4000B scanner (Axon Instruments Inc., Union City, CA, USA) using 532 nm excitation. Data processing and image analysis were performed using GenePixPro6.0 software (Axon Instruments Inc.). When the averaged signal intensity from hybridization was higher than both two standard values, background value (negative samples and blank control plus 3x SD) and cutoff value (15% of biotinylated control value), we considered the probe as true signal.

3. Results {#sec3}
==========

3.1. Multiplex RT-PCR and Microarray Testing {#sec3.1}
--------------------------------------------

Positive controls, including six cell lines, eight patient positive samples of known genotypes, and five constructed fusion fractions, were used to test primer pairs and reaction conditions in the multiplex PCR reactions ([Figure 3](#fig3){ref-type="fig"} and Supplementary Figure 1 (see Supplementary Material available online at <http://dx.doi.org/10.1155/2013/135086>)). The correct sequence results confirmed that we had got right specific bands by multiplex RT-PCR.

The fusion gene microarray was separated into four parts: acute lymphoblastic leukemia (ALL), acute myelogeneous leukemia (AML), chronic myelogeneous leukemia (CML), and reference control. We used *GUS*gene as an internal positive control. We divided 15 chromosomal aberrations into three groups: AML,*AML1-ETO*, *PML-RARA* and its variant rearrangements (*PLZF-RARA*, *NPM1-RARA*), *CBFB-MYH11*, and *MLL* rearrangements (*MLL-AF9*, *MLL-ENL*, *MLL-ELL*, *MLL-AF6*, and *MLL-AF10*); ALL,*MLL-AF4*, *TEL-AML1*, *E2A-PBX1*, *BCR-ABL* p190, and *SIL-TAL1*; CML, *BCR-ABL* p210 and p230. Each fusion gene included one probe for each partner and chimeric junction probes specific for each splice variant already known. The partner\'s probe was as positive control in each gene fusion event, which located upstream or downstream of the described breakpoint. *MLL* rearrangements only had each partner\'s probe. We spotted probes for each fusion gene in horizontal row, first chimeric junction probes then specific partner\'s probes, with continuous triplicate repeats. The biotinylated control probe was arranged in the top row and left column to position the probes and also to control fluorescence signal hybridization. After incubating in Cy3-SA, the fluorescence signal was detected on certain location.

The signal intensities of every three spotted probes were averaged. By trial and error, we confirmed that for each probe the average signal intensity from negative samples and blank control plus 3x SD was a background value of this probe. To remove the false positive signals, another standard value is established. We finally chose 15% of biotinylated control probe signal intensity as the second standard, the cutoff value, through the statistics on over 100 samples. When the signal intensity from hybridization was higher than both two standard values, the background value and cutoff value, we believed the probe as true signal. In addition, when the true signal included one chimeric junction probe and two partner\'s probes of the same fusion gene group, the result was considered to be positive; on the contrary, the result was considered to be negative.

Furthermore we constructed a series of plasmids for each splice variant of fusion genes studied here for optimizing all the probes. In addition, the microarray was also tested with eighteen control samples (six cell lines, eight patient positive samples, and five constructed fusion fractions) of known genotypes to check the reliability of the results ([Figure 3](#fig3){ref-type="fig"} and Supplementary Figure 1). [Figure 3](#fig3){ref-type="fig"} showed four examples, cell line KASUMI-1 with *AML1-ETO*, K-562 with *BCR-ABL* b3a2 splice variant, AML patient with *PML-RARA* S-form, and ALL patient with*E2A-PBX1*(I), respectively. As could be seen, the signal from the *GUS*-gene was present in all samples (row L).

To estimate the sensitivity of our approach, a limiting dilution experiment was carried out using positive controls. RNA from all positive controls (six leukemic cells and eight patient samples with unique translocations) was serially diluted in 10^−1^ steps up to 10^−4^ with RNA from HL-60 cells carrying no translocations. Diluted samples were then used in multiplex RT-PCR, followed by microarray hybridization. For different translocations, the sensitivity assays were detected in the following dilutions: KASUMI-1 10^−3^, NB-4 10^−2^, ME-1 10^−2^, THP-1 10^−3^, REH 10^−2^, K-562 10^−2^, *AML1-ETO* 10^−3^, *PML-RARA*(S-form) 10^−2^, *MLL-AF4* 10^−2^, *MLL-ENL* 10^−2^, *MLL-ELL* 10^−2^, *MLL-AF6* 10^−3^, *MLL-AF10* 10^−3^, *E2A-PBX1* 10^−3^, and *BCR-ABL* p190 10^−3^, which indicated that the multiplex assay might detect 2--20 ng targeted RNA.

We also carried out the precision of our approach. Repeatability was tested by total RNA from one positive cell line K-562 bearing a t(9;22) *BCR-ABL* b3a2 splice variant. The RNA was divided into three parts. Each part of RNA was processed for reverse transcription and multiplex RT-PCR. Finally, the three reaction productions were hybridized onto three individual microarrays. The three hybridization results were identical, positive for the *BCR-ABL* b3a2 translocation (data not shown). Reproducibility was blindly evaluated by three different operators in three independent experiments using total RNA from cell lines (three positive, Kasumi-1, THP-1, and REH, and one negative, HL-60). The mean reproducibility of operators and experiments was 100 and 100%, respectively ([Table 4](#tab4){ref-type="table"}). These repeatability and reproducibility results demonstrated that the multiplex RT-PCR-microarrays method had good intra- and interassay precision.

3.2. Patient Samples Testing {#sec3.2}
----------------------------

Bone marrow samples from 200 patients (74 AML, 115 ALL, and 11 CML) were analyzed blindly using the multiplex RT-PCR combined with microarrays method. Some examples were showed in [Figure 4(a)](#fig4){ref-type="fig"}.

In AML patients, 37.8% chromosomal aberrations were found. Most frequent translocations were t(15;17) *PML-RARA* (13.5%), t(8;21) *AML-ETO* (10.8%), and inv(16)(p13q22) *CBFB-MYH11* (6.8%). Among ten patients with *PML-RARA*, there were five long (L)-form (*bcr1*) and four short (S)-form (*bcr3*) transcripts. It was interesting that the one remaining patient number 57 might be V-form transcript, because of the only two signals of probes PML-L and RARA besides *GUS* ([Figure 4(a)](#fig4){ref-type="fig"}, patient number 57). The breakpoint of *PML* was located within exon 6 (base position 1683), belonging to *bcr2*, which was referred to as "variant" or V-form. Five *CBFB-MYH11* patients were all type A, which was consistent with previous findings that type A transcript was the major type in inv(16) positive patients.

In ALL the portion of patients carrying specific translocations was 23.5%. The most frequent translocation was cryptic translocation t(12;21) *TEL-AML1* (15.6%). In most cases, 15 of 18 patients with *TEL-AML1* were found *TEL*-*AML1*ex2 variants. Two patients had two variants *TEL*-*AML1*ex2 and *TEL*-*AML1*ex3 (weaker), owing to alternative splicing causing the skipping of *AML1* exon 2 in a minority of transcripts. The t(1;19) *E2A-PBX1*was found in 2.6%, t(4;11) *MLL-AF4* in 3.4%, and t(9;22) *BCR-ABL* p190 in 1.7%.

A relatively large proportion of CML patients were found t(9;22) *BCR-ABL* p210 about 72.7% including two transcripts with the b3a2 (45.4%) and b2a2 (27.2%). Perhaps, the amount of CML patients studied here was only 11, resulting in the fact that the positive portion was lower than expected.

Validation of the multiplex-microarray method was done either by cytogenetics, fluorescence *in situ* hybridization (FISH), or RT-PCR analysis for all 200 patient samples in the Department of Hematology of Shanghai Children\'s Medical Center, Ruijin Hospital, Changhai Hospital of Shanghai (Shanghai, China). The detailed information was listed in Supplementary Text 1 and Supplementary Table 1. The comparison of the two methods was shown in [Table 5](#tab5){ref-type="table"}, and the concordance was about 96.5%, except four in AML and three in ALL. It was noted that these seven samples were not involved in the assay. We also performed additional individual PCR reactions for all positive samples ([Figure 4(b)](#fig4){ref-type="fig"}). The results of both methods were almost identical.

4. Discussion {#sec4}
=============

Monoplex or multiplex RT-PCR techniques have been increasingly used to characterize chromosomal translocations found in leukemic cells, with numerous advantages over traditional cytogenetics and FISH, including shorter turn-around time, no requirement for dividing cells, and detection of cryptic translocations. A multiplex RT-PCR protocol to simultaneously detect 29 translocations had been shown to be effective for clinical screening, followed by series of identifying split-out analysis with primers specific for individual translocations \[[@B7]\]. It was still time- and labor- consuming. Here we facilitated the detection in a single PCR reaction (two rounds), in combination with the following microarrays to simultaneously detect a great variety of different fusion transcripts.

We chose the 15 most frequently occurring and well-defined chromosomal rearrangements in leukemia, covering up to 40--50% of childhood and adult AML and ALL and 90--95% of CML patients. These translocations have been regarded as diagnostic and prognostic markers, reflecting risk-stratification and appropriate therapy \[[@B16]--[@B18]\]. In general, patients with t(12;21) *TEL-AML1* fusion and t(1;19) *E2A-PBX1* fusion in ALL as well as t(8;21) *AML1-ETO* fusion, t(15;17) *PML-RARA* fusion, and inv(16) *CBFB-MYH11* fusion in AML have the most favorable outcome \[[@B18]--[@B20]\], whereas those with the t(9;22) *BCR-ABL* fusion and t(4;11) *MLL-AF4*fusion in ALL have dismal prognosis \[[@B21], [@B22]\]. *MLL* translocations are usually associated with unfavorable prognosis and poor outcome \[[@B23]\]. However, patients with the *MLL-AF9* translocation are clearly associated with a favorable outcome \[[@B24]\].

Compared with the previous reports \[[@B11]--[@B14], [@B25]\], the procedure established here had many advantages. First, the procedure here targeted more chromosomal translocations. We focused on about 15 chromosomal translocations, including more than 50 mRNA splice variants. However, the previous reports only had allowed the analysis of only a few rearrangements and one split variant in each fusion gene. For instance, the *AML*Fusion*Chip* \[[@B14]\] only included three major types of rearrangements in AML: *AML1-ETO*, *CBFB-MYH11*, and 11q23/*MLL* abnormalities (*MLL-AF9*, *MLL-ENL*, *MLL-AF6*, and *MLL-AF10*); the gel-based biochip developed by Nasedkina et al. \[[@B12]\] addressed 13 fusion variants in 7 leukemia translocations. Second, the range of detection was wider, covering AML, ALL, and CML. *AML*Fusion*Chip* was only limited to one leukemia group. Third, the operating steps were easier. The assay here used chimeric primers, amplifying different fusion transcripts in the same condition. In previous reports, it was necessary to perform the standard multiplex RT-PCR with multiple parallel nested PCR reactions.

A control gene was also used as an internal control to evaluate the RT-PCR reaction and hybridization process. *ABL*, *B2M*, and *GUS* were three candidate control genes for multiplex RT-PCR \[[@B15]\]. *ABL* is a more reliable control gene to compare diagnostic and MRD samples, yet there may be competition between *BCR-ABL*fusion transcripts and *ABL* gene when amplifying samples with t(9;22). However *GUS* gene is also similarly expressed in normal and diagnostic samples, and variation of *GUS* and fusion gene transcript expression are correlated. Based on these, we chose *GUS* as control gene in this study.

We also tested the sensitivity of positive controls. It was the fact that the sensitivity was weak in multiplex RT-PCR compared to single PCR reactions, especially for detection of minimal residual diseases. We could observe in this report that the sensitivity of our reactions was decreased one to two orders of magnitude, due to the existence of sixteen primers in first reaction round. However, in incipient patient diagnosed with leukemia, the cell source used for RNA preparations was usually greater than 90% leukemic blasts. Moreover, the use of microarrays could improve the efficiency of discriminating splice variants and minimize the risk of contamination. Thus this multiplex PCR-microarray assay was suitable for diagnosing *de novo* leukemia.

We had scaled up in this method of analysis 200 patients with 74 AML, 115 ALL, and 11 CML. In 6 AML and 9 ALL cases, the internal control band using multiplex-microarray could not be detected. This could be ascribed to insufficient amount or quantity of RNA. Four in AML and 3 in ALL samples were beyond the detection scope of the assay. With regard to AML, t(15;17)*PML-RARA*, t(8;21)*AML-ETO* and inv(16)(p13q22)*CBFB-MYH11* were mainly identified. In ALL, t(12,21)*TEL-AML1* was predominantly observed, while t(4,11)*MLL-AF4*, t(1,19)*E2A-PBX1*, and t(9,22)*BCR-ABL* p190 were less frequently identified. Two forms of *BCR-ABL* p210 in CML were found: b3a2 and b2a2 transcripts, and the proportion of b3a2 was a little higher than that of b2a2. The majority of splice variants in *PML-RARA*, *E2A-PBX1*, and *TEL-AML1* were *PML-RARA* L-form (50%), *E2A-PBX1*(I) (66.7%), and *TEL*-*AML1*ex2 (94.4%), respectively. In addition, we also detected a novel form of *PML-RARA*, besides L-form and S-form transcripts, classified as V-form transcripts. The statistics on the frequency of different splice variants might provide more profound and additional molecular characteristics of the majority fusion transcripts styles. This would eventually allow a more precise clinical diagnosis and optimization of therapy.

The multiplex PCR-microarray assay could also be applied to detect rare rearrangements, such as *PLZF-RARA*, *NPM1-RARA*, and *SIL-TAL1*. For *CBFB-MYH11* translocation, type A transcript accounted for more than 85% of the positive patients; two other transcripts (D and E) represented nearly 5% each, whereas all others represented unique cases \[[@B4]\]. We designed two reverse primers and MYH11 probes for type A and types D and E, respectively. It was indicated that there were other seven or novel transcripts though signal intensity of wild probes CBFB, MYH11-A, and MYH11-DE.

The rare chromosomal rearrangements, such as t(6;9)*DEK-CAN*, t(17;19)*E2A-HLF*, t(16;21)*TSL-ERG*, and t(3;21)*AML1-MDS1-(EVI1)*, and other *MLL* rearrangements were also worth adding the present pipeline. Although there was no independent prognostic significance, these aberrations could be very important in screening the potential chromosomal rearrangements.
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Supplementary Text 1: Methods for clinic diagnosis of 200 leukemia samples, including cytogenetic, FISH and RT-PCR analysis.

Supplementary Figure 1: Results from the multiplex RT-PCR combined with microarray for positive controls.

Supplementary Table 1: Multiplex RT-PCR - microarray and clinic diagnosis of 200 leukemia samples.
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![The illustration of the microarray. Left capital letters denoted the rows with specific fusion genes (A--K), and the chimeric junction probes and specific partner\'s probes for each fusion gene were marked by the numbers 1a, 1b, 1c--6a, 6b, 6c in triplicate. Row L represented the internal positive control *GUS* gene.](BMRI2013-135086.001){#fig1}

![The procedure of multiplex RT-PCR-microarray assay. (a) Steps of multiplex RT-PCR. Reverse transcription was performed on total RNA with multiple chimeric reverse primers. The resulting cDNA was amplified with two-round PCR. First round was amplified with multiple chimeric forward primers on the 5′ region (upstream of known translocation points) and universal primer SP6 on the 3′ region. Second round was with universal primer T7 and biotin labeled SP6, resulting in biotinylated complex. (b) Hybridization with microarray. Take the sample with *AML1-ETO* translocation as example.](BMRI2013-135086.002){#fig2}

![Results from the multiplex RT-PCR combined with microarray for positive controls. HL-60 and H~2~O were used as negative controls. (a) *AML1-ETO* in the cell line KASUMI-1. (b) *BCR-ABL* p210, b3a2 in the cell line K-562. (c) AML patient t(15;17) (*PML-RARA*) S-form. (d) ALL patient t(1;19) (*E2A-PBX1*). (I) Multiplex RT-PCR analysis. (II) Microarray analysis. (III) Histogram of data obtained from microarray. The solid line indicated the cutoff value (15% of biotinylated control probe signal intensity). The dashed line indicated the background value (negative samples and blank control plus 3x SD). Signals over both the cutoff and background control were recognized as true signals (in red circle). (IV) Sequence of multiplex RT-PCR products.](BMRI2013-135086.003){#fig3}

![Representative results of fusion genes. (a) Multiplex RT-PCR analysis and the microarray results of 19 clinic samples (10 AML, 7 ALL, and 2 CML). HL-60 and H~2~O were used as negative controls. (b) RT-PCR validation of the microarray positive samples.](BMRI2013-135086.004){#fig4}

###### 

Chromosomal alterations included in the multiplex RT-PCR analysis.

  --------------------------------------------------------------------------------------------------------------
  Chromosome aberration   Genes involved^a^   Accession number   Positive controls                 
  ----------------------- ------------------- ------------------ ------------------- ------------- -------------
  t(8;21)(q22;q22)\       *AML1* (21q22)      D43969             KASUMI-1                          
  *AML1-ETO*                                                                                       

  *ETO* (8q22)            D14289                                                                   

  t(15;17)(q22;q21)\      *PML* (15q22)       M73778             NB-4                \+ (S form)   
  *PML-RARA*                                                                                       

  *RARA* (17q21)          X06538                                                                   

  t(11;17)(q23;q21)\      *PLZF*(11q23)       Z19002                                               \+
  *PLZF-RARA*                                                                                      

  *RARA* (17q21)          X06538                                                                   

  t(5;17)(q35;q22)\       *NPM1* (5q35)       X16934                                               \+ (S form)
  *NPM1-RARA*                                                                                      

  *RARA* (17q21)          X06538                                                                   

  inv(16)(p13q22)\        *CBFB* (16q22)      L20298             ME-1                              \+ (type D)
  *CBFB-MYH11*                                                                                     

  *MYH11* (16p13)         D10667                                                                   

  t(12;21)(p13;q22)\      *TEL*(12p13)        U11732             REH                               
  *TEL-AML1*                                                                                       

  *AML1* (21q22)          D43969                                                                   

  t(1;19)(q23;p13)\       *E2A* (19p13)       M31222                                 \+            
  *E2A-PBX1*                                                                                       

  *PBX1* (1q23)           M86546                                                                   

  t(9;22)(q34;q11)\       *BCR* (22q11)       X02596             K-562 (p210)        \+ (p190)     \+ (p230)
  *BCR-ABL*                                                                                        

  *ABL* (9q34)            X16416                                                                   

  del(1)(p32;p32)\        *SIL* (1p34)        M74558                                               \+ (type I)
  *SIL-TAL1*                                                                                       

  *TAL1* (1p34)           S53245                                                                   

  t(4;11)(q21;q23)\       *MLL* (11q23)       L04284                                 \+            
  *MLL-AF4*                                                                                        

  *AF4* (4q21)            L13773                                                                   

  t(9;11)(p22;q23)\       *MLL* (11q23)       L04284             THP-1                             
  *MLL-AF9*                                                                                        

  *AF9*(9p22)             L13744                                                                   

  t(11;19)(q23;p13.3)\    *MLL* (11q23)       L04284                                 \+            
  *MLL-ENL*                                                                                        

  *ENL* (19p13.3)         D14539                                                                   

  t(11;19)(q23;p13.1)\    *MLL* (11q23)       L04284                                 \+            
  *MLL-ELL*                                                                                        

  *ELL* (19p13.1)         U16282                                                                   

  t(6;11)(q27;q23)\       *MLL* (11q23)       L04284                                 \+            
  *MLL-AF6*                                                                                        

  *AF6*(6q27)             U02478                                                                   

  t(10;11)(p12;q23)\      *MLL* (11q23)       L04284                                 \+            
  *MLL-AF10*                                                                                       

  *AF10* (10p12)          U13948                                                                   
  --------------------------------------------------------------------------------------------------------------

^a^Chromosomes on which genes are located are in brackets.

^b^Cells were kindly provided by Ruijin Hospital (Shanghai, China).

^c^Patients RNAs were kindly provided by Shanghai Children\'s Medical Center (Shanghai, China).

###### 

Chimeric primers used in the multiplex RT-PCR.

  Primer name   Primer composition (size)^a^   Sequence (5′ to 3′)
  ------------- ------------------------------ -------------------------------------------------
  ETO_R         D14289_SP6_614 (18)            ATTTAGGTGACACTATAGA GAACTCTTTCTCCTATCT
  RARA_R        X06538_SP6_696 (16)            ATTTAGGTGACACTATAGA CGGTCGTTTCTCACAG
  MYH11-A_R     D10667_SP6_2271 (18)           ATTTAGGTGACACTATAGA TTGCGTAGCTGCTTGATG
  MYH11-DE_R    D10667_SP6_1374 (15)           ATTTAGGTGACACTATAGA GCAGGCTGTTCCGCT
  AML1_R        D43969_SP6_731 (17)            ATTTAGGTGACACTATAGA CACGGAGCAGAGGAAGT
  PBX1_R        M86546_SP6_657 (19)            ATTTAGGTGACACTATAGA TCGCAGGAGATTCATCACG
  TAL1_R        S53245_SP6_257 (15)            ATTTAGGTGACACTATAGA CGTCCCTCTAGCTGG
  ABL_R         X16416_SP6_576 (17)            ATTTAGGTGACACTATAGA AGCTGCCATTGATCCCG
  AF9_R         L13744_SP6_1910 (20)           ATTTAGGTGACACTATAGA TTCTTGATGCATCCAGTTGT
  ENL_R         D14539_SP6_301 (20)            ATTTAGGTGACACTATAGA GACCACCTTCTCCACGAAGT
  ELL_R         U16282_SP6_461 (17)            ATTTAGGTGACACTATAGA GTAGCGGCCTCCAGCCT
  AF6_R         U02478_SP6_360 (18)            ATTTAGGTGACACTATAGA AATCTGCCTTCCCGATCA
  AF10-A_R      U13948_SP6_2384 (19)           ATTTAGGTGACACTATAGA CACTGCCTCTCCAAAAGCT
  AF10-B_R      U13948_SP6_1146 (18)           ATTTAGGTGACACTATAGA TGACCTGAGCTGTGAGCT
  AF4_R         L13773_SP6_1674 (18)           ATTTAGGTGACACTATAGA TCGAGCATGGATGACGTT
  GUS_R         M15182_SP6_2057 (18)           ATTTAGGTGACACTATAGA TGCCGTGAACAGTCCAGG
  AML1_F        D43969_T7_903 (22)             TAATACGACTCACTATAGGGA CCAGGTTGCAAGATTTAATGAC
  PML-L_F       M73778_T7_1438 (19)            TAATACGACTCACTATAGGGA CAGTGTACGCCTTCTCCATCA
  PML-S_F       M73778_T7_927 (25)             TAATACGACTCACTATAGGGA GTGCGCCAGGTGGTAGCTC
  PLZF_F        Z19002_T7_1092(21)             TAATACGACTCACTATAGGGA CCACAAGGCTGACGCTGTATT
  NPM1_F        X16934_T7_160 (25)             TAATACGACTCACTATAGGGA ACGAAGGCAGTCCAATTAAAGTAAC
  CBFB_F        L20298_T7_267 (22)             TAATACGACTCACTATAGGGA TTTGAAGGCTCCCATGATTCTG
  TEL_F         U11732_T7_871 (23)             TAATACGACTCACTATAGGGA CACTCCGTGGATTTCAAACAGTC
  E2A_F         M31222_T7_1243 (22)            TAATACGACTCACTATAGGGA AAGATAGAAGACCACCTGGACG
  SIL_F         M74558_T7_24 (19)              TAATACGACTCACTATAGGGA CGACCCCAACGTCCCAGAG
  BCR-190_F     X02596_T7_1590 (20)            TAATACGACTCACTATAGGGA CGCTCTCCCTCGCAGAACT
  BCR-210_F     X02596_T7_2952 (24)            TAATACGACTCACTATAGGGA GAGTCACTGCTGCTGCTTATGTC
  BCR-230_F     X02596_T7_3682 (19)            TAATACGACTCACTATAGGGA CCAAGGTGCCCTACATCGT
  MLL_F         L04284_T7_3916 (20)            TAATACGACTCACTATAGGGA CCGCCTCAGCCACCTACTAC
  GUS_F         M15182_T7_1786 (20)            TAATACGACTCACTATAGGGA GGAATTTTGCCGATTTCATG
  T7                                           TAATACGACTCACTATAGGGA
  SP6                                          ATTTAGGTGACACTATAGA
  SP6-biotin                                   biotin-ATTTAGGTGACACTATAGA

\_R: reverse primer, \_F: forward primer.

^a^Primer composition was given with gene accession number plus universal gene (T7 or SP6), the starting position on the gene, and total length in brackets.

###### 

Sequence of oligonucleotide probes used on the microarray.

  Chromosome aberration   Gene name      Fusion variants   Probe name      Sequence (5′ to 3′)                       Position on microarray
  ----------------------- -------------- ----------------- --------------- ----------------------------------------- ------------------------
  t(8;21)(q22;q22)        *AML1-ETO*     *AML1-ETO*        AML1-ETO        CCCGAGAACCTCGAAATCGTACTGAGAAG             A-1abc
                                                           AML1ex5         CTCAGGTTTGTCGGTCGAAGTGGAAGAGG             A-2abc
                                                           ETO             GCCAGACTCACCTGTGGATGTGAAGACGCAA           A-3abc
                                                                                                                     
  t(15;17)(q22;q21)       *PML-RARA*     L-form            PML-RARA-L      CCGGGGAGGCAGCCATTGAGACCCAGAG              B-1abc
                                         S-form            PML-RARA-S      CACCCAGGGGAAAGCCATTGAGACCCAGAG            B-2abc
                                                           PML-L           CAGAAGAGGAAGTGCAGCCAGACCCAGTGCC           B-3abc
                                                           PML-S           AGAGGATGAAGTGCTACGCCTCGGACCAG             B-4abc
                                                           RARA            CCCTCTACCCCGCATCTACAAGCCTTGCTT            B-5abc
                                                                                                                     
  t(11;17)(q23;q21)       *PLZF-RARA*    *PLZF-RARA*       PLZF-RARA       CTTACTGGCTCATTCAGCCATTGAGACCCAGA          C-1abc
                                                           PLZF            GGGATGAAGACGTACGGGTGCGAGCTCTG             C-2abc
                                                                                                                     
  t(5;17)(q35;q22)        *NPM1-RARA*    L-form            NPM1-RARA-L-1   AGGAGGAGGATGTGAACAGGGTTTTATTTATGAA        C-3abc
                                         S-form            NPM1-RARA-L-2   GTTGGAAATTGGCAGCCATTGAGACCCAGA            C-4abc
                                                           NPM1-RARA-S     GTGGACAGCACTTAGTAGCCATTGAGACCCAGA         C-5abc
                                                           NPM1            ACACCACCAGTGGTCTTAAGGTTGAAGTGTGG          C-6abc
                                                                                                                     
  inv(16)(p13q22)         *CBFB-MYH11*   A                 CBFB-MYH11-A    CGGGAGGAAATGGAGGTCCATGAGCTGGAGA           D-1abc
                                         D                 CBFB-MYH11-D    CGGGAGGAAATGGAGAATGAAGTTGAGAGCG           D-2abc
                                         E                 CBFB-MYH11-E    CGGGAGGAAATGGAGGCCAAGGCGAACC              D-3abc
                                                           CBFB            CACGCGAATTTGAAGATAGAGACAGGTCTCA           D-4abc
                                                           MYH11-A         ACCCAGATGGAGGAGATGAAGACGCAGC              D-5abc
                                                           MYH11-DE        GACACCCAGGAGTTGCTTCAAGAA                  D-6abc
                                                                                                                     
  t(12;21)(p13;q22)       *TEL-AML1*     *TEL-AML1*ex2     TEL-AML1ex2     ATTGGGAGAATAGCAGAATGCATACTTGGAATG         G-1abc
                                         *TEL-AML1*ex3     TEL-AML1ex3     ATTGGGAGAATAGCAGATGCCAGCACGAGC            G-2abc
                                                           TEL             ATCGGGAAGACCTGGCTTACATGA                  G-3abc
                                                           AML1ex3         GCCGCTTCACGCCGCCTTCCACCGC                 G-4abc
                                                                                                                     
  t(1;19)(q23;p13)        *E2A-PBX1*     I                 E2A-PBX1-I      CCCGACTCCTACAGTGTTTTGAGTATCCGAGG          H-1abc
                                         Ia                E2A-PBX1-Ia     TACAGTGATGAAAGTGTTCGGTCACCTGGAACCTTTTTG   H-2abc
                                                           E2A             CCTCAGGTTTCACCGGCCCCATGTCACT              H-3abc
                                                           PBX1            TGGACAACATGCTGTTAGCGGAAGGCGTGG            H-4abc
                                                                                                                     
  t(9;22)(q34;q11)        *BCR-ABL*      p190              p190            TTCCATGGAGACGCAGAAGCCCTTCAGCGGC           J-1abc
                                         p210 b2a2         p210-b2a2       TGACCATCAATAAGGAAGAAGCCCTTCAGCG           K-1abc
                                         p210 b3a2         p210-b3a2       CTGGATTTAAGCAGAGTTCAAAAGCCCTTCAGCGGC      K-2abc
                                         p230              p230            AGCCTTCGACGTCAAAGCCCTTCAGCG               K-4abc
                                                           BCR190          GGGCGTCCGCAAGACCGGGCAGATCTGG              J-2abc
                                                           BCR210          AGAACATCCGGGAGCAGCAGAAGAAGTGTTT           K-3abc
                                                           BCR230          TGGAGGAGATCGAGCGCCGAGGCATGGAGG            K-5abc
                                                           ABL             CCAAGGCTGGGTCCCAAGCAACTACATCACG           K-6abc
                                                                                                                     
  del(1)(p32;p32)         *SIL-TAL1*     I                 SIL-TAL1-I      CGCGGAAGTTGCGGATGACCGAGCGGC               I-1abc
                                         II                SIL-TAL1-II     CGCGGAAGTTGCGATCGCCCAGGACCA               I-2abc
                                         III               SIL-TAL1-III    CCTCCCAAAATGCTGATCGCCCAGGACCA             I-3abc
                                                           SIL             GGCTCCCGCTCCTACCCTGCAAACAGA               I-4abc
                                                           TAL1            GCCGAGCGAGGCGGCTCGCAGTGACCC               I-5abc
                                                                                                                     
  t(4;11)(q21;q23)        *MLL-AF4*                        MLL             CCCAAAACCACTCCTAGTGAGCCCA                 F-1abc
                                                           AF4             TCAAAAACTCACTCAAATTCTCAGCAAG              F-2abc
                                                                                                                     
  t(9;11)(p22;q23)        *MLL-AF9*                        AF9             ACCTGGAAACATCTGGAACATCCTGAGGA             E-1abc
                                                                                                                     
  t(11;19)(q23;p13.3)     *MLL-ENL*                        ENL             GGGTTCACTCACGACTGGATGGTGTTTGTCCG          E-2abc
                                                                                                                     
  t(11;19)(q23;p13.1)     *MLL-ELL*                        ELL             CCAGCAGTATGTCTCCAGTCATGGGGAAGT            E-3abc
                                                                                                                     
  t(6;11)(q27;q23)        *MLL-AF6*                        AF6             TTCGACCTGATATGCGAATGCTGTCCTCTC            E-4abc
                                                                                                                     
  t(10;11)(p12;q23)       *MLL-AF10*     A:2222            AF10-A          GCTTACAGATTCGCTATGATCAACCAGGCA            E-5abc
                                         B:979             AF10-B          GTTTCAGAGACTAGAGGGTCAGAGGGCA              E-6abc
                                                                                                                     
                          *GUS*                            GUS             CAGTCACCGACGAGAGTGCTGGGGA                 L-1abc, 3abc, 5abc

###### 

Reproducibility of operators and experiments.

  Operator                       RNA             Experiment 1    Experiment 2    Experiment 3   Reproducibility of experiments   
  ------------------------------ --------------- --------------- --------------- -------------- -------------------------------- ---
  Operator 1                     Kasumi-1        *AML1-ETO*      *AML1-ETO*      *AML1-ETO*                                       
  THP-1                          *MLL-AF9*       *MLL-AF9*       *MLL-AF9*       100%                                            
  REH                            *TEL-AML1*ex2   *TEL-AML1*ex2   *TEL-AML1*ex2                                                   
  HL-60                          None            None            None                                                            
                                                                                                                                 
  Operator 2                     Kasumi-1        *AML1-ETO*      *AML1-ETO*      *AML1-ETO*                                       
  THP-1                          *MLL-AF9*       *MLL-AF9*       *MLL-AF9*       100%           100%                             
  REH                            *TEL-AML1*ex2   *TEL-AML1*ex2   *TEL-AML1*ex2                                                   
  HL-60                          None            None            None                                                            
                                                                                                                                 
  Operator 3                     Kasumi-1        *AML1-ETO*      *AML1-ETO*      *AML1-ETO*                                       
  THP-1                          *MLL-AF9*       *MLL-AF9*       *MLL-AF9*       100%                                            
  REH                            *TEL-AML1*ex2   *TEL-AML1*ex2   *TEL-AML1*ex2                                                   
  HL-60                          None            None            None                                                            
                                                                                                                                 
  Reproducibility of operators                   100%            100%            100%                                             
                                                 100%                                                                            

###### 

Summary of translocations detected by multiplex RT-PCR-microarray method and clinic diagnostic analysis.

  Translocations                                 Multiplex RT-PCR-microarrays   Clinic diagnosis^a^                   
  ---------------------------------------------- ------------------------------ --------------------- ---- ---- ----- ----
  t(8;21) *AML1-ETO*                             8                                                         8           
  t(15;17) *PML-RARA*                            10                                                        10          
  inv(16) *CBFB-MYH11*                           5                                                         5           
  t(9;11) *MLL-AF9*                              1                                                         1           
  t(11;19) *MLL-ENL*                             1                                                         1           
  t(11;19) *MLL-ELL*                             1                                                         1           
  t(6;11) *MLL-AF6*                              1                                                         1           
  t(10;11) *MLL-AF10*                            1                                                         1           
  t(4;11) *MLL-AF4*                                                             4                               4      
  t(12;21) *TEL-AML1*                                                           18                              18     
  t(1;19) *E2A-PBX1*                                                            3                               3      
  t(9;22) *BCR-ABL* p190                                                        2                               2      
  t(9;22) *BCR-ABL* p210                                                                              8               8
  Other translocations                                                                                     4    3      
  Total number of patients with translocations   28                             27                    8    32   30    8
  Total number of patients                       74                             115                   11   74   115   11

^a^Clinic diagnosis was carried out by either cytogenetic, FISH, or RT-PCR analysis.

[^1]: Academic Editor: Luca Arcaini
